Literature DB >> 10334507

Enzymatic inactivation of major circulating forms of atrial and brain natriuretic peptides.

J Ozaki1, H Shimizu, Y Hashimoto, H Itoh, K Nakao, K Inui.   

Abstract

We compared the enzymatic inactivation of major circulating forms of atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP). Both ANP and BNP induced a significant increase in cyclic GMP (cGMP) formation in cultured epithelial cell line derived from porcine kidney, LLC-PK1. The cGMP formation stimulated by ANP in LLC-PK1 cells was significantly decreased by pre-treatment of the peptide with rat renal brush-border membranes, and the inactivation of ANP was inhibited by neutral endopeptidase inhibitors, phosphoramidon and S-thiorphan. BNP exhibited greater resistance to enzymatic inactivation than did ANP. In addition, phosphoramidon potentiated the natriuresis with a low dose (7.5 pmol min(-1) kg(-1)) of ANP but not of BNP in rats. These results suggest that enzymatic degradation of natriuretic peptides is highly dependent on peptide structure, and that the affinity of BNP to neutral endopeptidase is less than that of ANP.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10334507     DOI: 10.1016/s0014-2999(99)00115-6

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  6 in total

Review 1.  Role of bradykinin in preconditioning and protection of the ischaemic myocardium.

Authors:  G F Baxter; Z Ebrahim
Journal:  Br J Pharmacol       Date:  2002-02       Impact factor: 8.739

2.  Does impaired processing of pro-B-type (or brain) natriuretic peptide cause decreased plasma BNP levels in obese heart failure patients?

Authors:  Toshio Nishikimi; Yasuaki Nakagawa
Journal:  Ann Transl Med       Date:  2019-09

3.  Effect of neutral endopeptidase inhibitor on endogenous atrial natriuretic peptide as a paracrine factor in cultured cardiac fibroblasts.

Authors:  T Maki; T Horio; F Yoshihara; S Suga; S Takeo; H Matsuo; K Kangawa
Journal:  Br J Pharmacol       Date:  2000-11       Impact factor: 8.739

Review 4.  B-type natriuretic peptide and renal disease.

Authors:  Peter A McCullough; Keisha R Sandberg
Journal:  Heart Fail Rev       Date:  2003-10       Impact factor: 4.214

Review 5.  B-Type Natriuretic Peptide (BNP) Revisited-Is BNP Still a Biomarker for Heart Failure in the Angiotensin Receptor/Neprilysin Inhibitor Era?

Authors:  Toshio Nishikimi; Yasuaki Nakagawa
Journal:  Biology (Basel)       Date:  2022-07-09

Review 6.  A review on B-type natriuretic peptide monitoring: assays and biosensors.

Authors:  Rita Maalouf; Steven Bailey
Journal:  Heart Fail Rev       Date:  2016-09       Impact factor: 4.214

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.